Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Forum
  • About Us
    • Our Coverage
    • Team
Third party research

Physitrack: Delivery on track - ABG

Physitrack

This is a third party research report and does not necessarily reflect our views or values

Download report (PDF)
Pro forma growth in line with company target Margin slightly pressured by virtual care acquisitionsTrading at 14 ‘23e EV/EBITDA

Wellness segment showed strong pro forma growth The report was largely in line with our expectations when looking at sales and adj. EBITDA, and we highlight that the wellness segment showed solid pro forma revenue growth y-o-y of 44%. Subscription revenues were slightly below our expectations, but still managed to grow 27% y-o-y pro forma (Lifecare Technology division). On opex, the company continues to invest in future growth, and we believe the transition to an in-house technology team could have put some short-term pressure on the margin. As well, some revenues have been shifted towards a subscription-based model which pushes back revenues. The EBIT margin came in well below our expectations, which can largely be explained by higher acquisition-related amortisations than we expected, thus not affecting the EBITA margin.

Solid ARR development and improving churn set to continueARR at end-quarter was EUR 9.8m, up 29% q-o-q and partly boosted by the consolidation of Champion Health. However, as the company is transitioning some of its non-recurring revenue to a subscription-based model, the ARR should see solid growth ahead. In addition, we note that the rolling 12-month churn rate continues to improve, which we find encouraging; it is now down to 1.3% (monthly basis). However, we believe there remains room for improvement, and it seemed like a focus point when CEO Henrik Molin mentioned it on the conference call.

Estimate revisions and valuationWe raise our sales estimates slightly, primarily following the strong Virtual Care growth. The CEO also commented on the macroeconomic environment, which did not appear to have weighed on growth – quite the opposite, in fact, providing further support to our sales estimates. On costs, we raise opex ex. D&A largely in line with our sales revisions, but adjust D&A, primarily acquisition-related amor...Läs mer på ABG Sundal Collier
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Forum
  • About Us
    • Our Coverage
    • Team

Privacy preferences

Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.